ZA201407835B - Methods an means for the production of ig-like molecules - Google Patents

Methods an means for the production of ig-like molecules

Info

Publication number
ZA201407835B
ZA201407835B ZA2014/07835A ZA201407835A ZA201407835B ZA 201407835 B ZA201407835 B ZA 201407835B ZA 2014/07835 A ZA2014/07835 A ZA 2014/07835A ZA 201407835 A ZA201407835 A ZA 201407835A ZA 201407835 B ZA201407835 B ZA 201407835B
Authority
ZA
South Africa
Prior art keywords
molecules
production
methods
Prior art date
Application number
ZA2014/07835A
Other languages
English (en)
Inventor
Linda Johanna Aleida Hendriks
Ton Logtenberg
Kruif Cornelis Adriaan De
Original Assignee
Merus B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201407835(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus B V filed Critical Merus B V
Publication of ZA201407835B publication Critical patent/ZA201407835B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
ZA2014/07835A 2012-04-20 2014-10-27 Methods an means for the production of ig-like molecules ZA201407835B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261635935P 2012-04-20 2012-04-20
PCT/NL2013/050293 WO2013157953A1 (en) 2012-04-20 2013-04-19 Methods and means for the production of ig-like molecules

Publications (1)

Publication Number Publication Date
ZA201407835B true ZA201407835B (en) 2015-12-23

Family

ID=48289584

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2014/07835A ZA201407835B (en) 2012-04-20 2014-10-27 Methods an means for the production of ig-like molecules
ZA2014/07834A ZA201407834B (en) 2012-04-20 2014-10-27 Methods and means for the production of ig-like molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2014/07834A ZA201407834B (en) 2012-04-20 2014-10-27 Methods and means for the production of ig-like molecules

Country Status (24)

Country Link
US (12) US20150196637A1 (enExample)
EP (4) EP2838917B1 (enExample)
JP (9) JP6393255B2 (enExample)
KR (9) KR20250025034A (enExample)
CN (6) CN104520319B (enExample)
AU (4) AU2013249985B2 (enExample)
CA (2) CA2870821C (enExample)
CY (2) CY1122153T1 (enExample)
DK (2) DK2838918T3 (enExample)
EA (3) EA201491908A1 (enExample)
ES (2) ES2740749T3 (enExample)
HR (2) HRP20191446T1 (enExample)
HU (2) HUE045944T2 (enExample)
LT (2) LT2838917T (enExample)
MX (7) MX360109B (enExample)
NZ (4) NZ772318A (enExample)
PL (2) PL2838917T3 (enExample)
PT (2) PT2838918T (enExample)
RS (2) RS59263B1 (enExample)
SG (6) SG10201607369QA (enExample)
SI (2) SI2838918T1 (enExample)
SM (2) SMT201900493T1 (enExample)
WO (2) WO2013157954A1 (enExample)
ZA (2) ZA201407835B (enExample)

Families Citing this family (464)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
SG174053A1 (en) 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
CN103298937B (zh) 2010-11-17 2016-05-25 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
MX356947B (es) 2011-08-23 2018-06-20 Roche Glycart Ag Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN109111524B (zh) 2011-10-31 2022-10-28 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
MX2014009129A (es) * 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
DK2900694T3 (en) 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
EP3878964A1 (en) 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
KR20180023035A (ko) 2013-02-26 2018-03-06 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
PE20151925A1 (es) 2013-04-29 2015-12-26 Hoffmann La Roche Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
SG11201605044RA (en) 2013-12-20 2016-07-28 Hoffmann La Roche HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
RU2693438C2 (ru) 2014-01-03 2019-07-02 Ф. Хоффманн-Ля Рош Аг Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
JP6557664B2 (ja) 2014-01-06 2019-08-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価の血液脳関門シャトルモジュール
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
SG11201607983YA (en) 2014-03-28 2016-10-28 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
EP3126389B1 (en) 2014-04-02 2024-10-23 F. Hoffmann-La Roche AG Method for detecting multispecific antibody light chain mispairing
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
BR112016029935A2 (pt) 2014-06-26 2017-10-31 Hoffmann La Roche ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
PE20211533A1 (es) 2014-08-04 2021-08-16 Hoffmann La Roche Moleculas biespecificas de unon a antigeno activadoras de celulas t
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016055592A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
HRP20191766T1 (hr) 2014-11-06 2019-12-27 F. Hoffmann - La Roche Ag Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene
EP3842453A1 (en) 2014-11-06 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and protein a-binding properties
HRP20201928T1 (hr) 2014-11-20 2021-02-05 F. Hoffmann - La Roche Ag Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
MX2017006571A (es) 2014-11-20 2017-09-29 Hoffmann La Roche Moleculas de union a antigeno biespecificas activadoras de celulas t.
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
RS62332B1 (sr) 2014-11-26 2021-10-29 Xencor Inc Heterodimerna antitela koja vezuju cd3 i cd20
CN107406512A (zh) 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
CN110658340B (zh) * 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP2018510637A (ja) 2015-03-26 2018-04-19 アクセルロン ファーマ， インコーポレイテッド フォリスタチン関連融合タンパク質およびその使用
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
PT3319993T (pt) 2015-07-10 2020-04-22 Genmab As Conjugados de anticorpo-fármaco específicos de axl para tratamento de cancro
JP7010811B2 (ja) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ ヒトｃｄ３結合抗体
BR112018000696A2 (pt) 2015-07-15 2018-09-18 Genmab As ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
CN107106682B (zh) 2015-08-26 2021-05-25 比森医疗股份有限公司 多特异性抗体平台和相关方法
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
IL257110B (en) 2015-10-02 2022-09-01 Hoffmann La Roche Bispecific antibodies specific against pd1 and tim3
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
AR106365A1 (es) 2015-10-02 2018-01-10 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
EP3356409A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific t cell activating antigen binding molecules
EP3913000A1 (en) 2015-10-02 2021-11-24 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
CN108139394B (zh) 2015-10-02 2020-10-30 豪夫迈·罗氏有限公司 用于确定同时结合的基于细胞的fret测定法
EP3150637A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Multispecific antibodies
WO2017055395A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
WO2017072210A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
WO2017072208A1 (en) * 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Transgenic rabbit with common light chain
WO2017093447A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CN106883297B (zh) 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
RS64266B1 (sr) 2016-03-22 2023-07-31 Hoffmann La Roche Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom
WO2017186853A1 (en) * 2016-04-27 2017-11-02 Bcrt Holding Bv T cell-based bi-specific immunotherapeutics
MX2018012648A (es) 2016-04-28 2019-01-30 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos.
EP3889175A1 (en) 2016-05-02 2021-10-06 F. Hoffmann-La Roche AG The contorsbody - a single chain target binder
CN109475627B (zh) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
MA45672A (fr) 2016-07-14 2019-05-22 Biontech Ag Anticorps multispécifiques dirigés contre cd40 et cd137
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2017332452B2 (en) 2016-09-23 2021-01-07 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
EP3504234A4 (en) * 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
WO2018060035A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Spr-based dual-binding assay for the functional analysis of multispecific molecules
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
MA46534A (fr) 2016-10-14 2019-08-21 Xencor Inc Protéines de fusion fc hétérodimères il15/il15r
CN118359705A (zh) * 2016-10-19 2024-07-19 英温拉公司 抗体构建体
US20190276549A1 (en) 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
SG10201913260VA (en) 2016-11-18 2020-03-30 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
US11111305B2 (en) 2017-01-09 2021-09-07 Torch Therapeutics Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3053222A1 (en) 2017-02-10 2018-08-16 Genmab B.V. Polypeptide variants and uses thereof
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
US12054544B2 (en) * 2017-02-24 2024-08-06 Chugai Seiyaku Kabushiki Kaisha Compositions comprising antigen-binding molecules
LT3592769T (lt) 2017-03-09 2024-08-26 Genmab A/S Antikūnai, atpažįstantys pd-l1
CN110402253B (zh) 2017-03-10 2024-01-05 豪夫迈·罗氏有限公司 用于生产多特异性抗体的方法
WO2018182420A1 (en) 2017-03-31 2018-10-04 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
WO2018178396A1 (en) 2017-03-31 2018-10-04 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3600413A1 (en) 2017-03-31 2020-02-05 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
CN111032081A (zh) 2017-03-31 2020-04-17 美勒斯公司 ErbB-2和ErbB-3靶向剂和双特异性抗体
SG11201909156RA (en) * 2017-04-01 2019-10-30 Beijing hanmi pharm co ltd Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
EP4516809A3 (en) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
BR112019021411A2 (pt) 2017-04-13 2020-05-05 Hoffmann La Roche métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
KR102744809B1 (ko) 2017-05-17 2024-12-23 메뤼스 엔.페. 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JP2020522543A (ja) 2017-06-07 2020-07-30 ゲンマブ ビー．ブイ． 変異ＩｇＧ六量体に基づく治療用抗体
WO2018228442A1 (en) * 2017-06-14 2018-12-20 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
US11667714B2 (en) 2017-07-06 2023-06-06 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
KR20200037250A (ko) 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
CA3068932A1 (en) 2017-07-06 2019-01-10 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
WO2019014912A1 (zh) * 2017-07-21 2019-01-24 赵磊 一种异二聚体蛋白及其制备方法
CN111406067B (zh) 2017-08-04 2022-11-08 健玛保 与pd-l1和cd137结合的结合剂及其用途
PL3665198T3 (pl) 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
TW201930351A (zh) 2017-10-06 2019-08-01 日商小野藥品工業股份有限公司 雙特異性抗體
JP7450535B2 (ja) 2017-10-20 2024-03-15 エフ． ホフマン－ラ ロシュ アーゲー 単一特異性抗体から多重特異性抗体を生成させるための方法
TWI832824B (zh) 2017-10-30 2024-02-21 瑞士商赫孚孟拉羅股份公司 自單特異性抗體於活體內產生多特異性抗體之方法
PL3704146T3 (pl) 2017-11-01 2022-03-07 F. Hoffmann-La Roche Ag Przeciwciało Contorsbody trifab
EP3703746A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Novel tnf family ligand trimer-containing antigen binding molecules
IL272747B2 (en) 2017-11-01 2025-04-01 Hoffmann La Roche Bispecific antibodies 1 + 2
WO2019086394A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
SG11202003833TA (en) 2017-11-01 2020-05-28 Chugai Pharmaceutical Co Ltd Antibody variant and isoform with lowered biological activity
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
WO2019108065A1 (en) 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
JP7231641B2 (ja) * 2017-12-04 2023-03-01 北京韓美薬品有限公司 天然抗体様構造を有し、ヘテロ二量体形態の抗ｐｄ－ｌ１／抗ｃｄ４７二重特異性抗体、ならびにその製造方法
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
TWI805665B (zh) 2017-12-21 2023-06-21 瑞士商赫孚孟拉羅股份公司 結合hla-a2/wt1之抗體
JP7074859B2 (ja) 2017-12-22 2022-05-24 エフ．ホフマン－ラ ロシュ アーゲー 疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
JP2021510740A (ja) 2018-01-24 2021-04-30 ゲンマブ ビー．ブイ． ポリペプチド変種およびそれらの用途
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN118772288A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
JP2021512624A (ja) * 2018-02-11 2021-05-20 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
TW202003569A (zh) * 2018-03-30 2020-01-16 荷蘭商美勒斯公司 多價抗體
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
BR112020020823A2 (pt) 2018-04-09 2021-01-19 Amgen Inc. Proteínas de fusão do fator de diferenciação do crescimento 15
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
WO2019211472A1 (en) 2018-05-03 2019-11-07 Genmab B.V. Antibody variant combinations and uses thereof
CN120285175A (zh) 2018-05-16 2025-07-11 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
KR20210016448A (ko) 2018-06-01 2021-02-15 컴퓨젠 엘티디. 항-pvrig/항-tigit 이중특이적 항체 및 사용 방법
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
KR20210031932A (ko) 2018-07-13 2021-03-23 젠맵 에이/에스 Cd38 항체의 변이체 및 그의 용도
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
CA3108646A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
CA3113409A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
WO2020070313A1 (en) 2018-10-04 2020-04-09 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
WO2020089051A1 (en) 2018-10-29 2020-05-07 F. Hoffmann-La Roche Ag Antibody formulation
WO2020094744A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
CA3121699A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
EP3898685A1 (en) 2018-12-20 2021-10-27 Merus N.V. Clec12axcd3 bispecific antibodies and methods for the treatment of disease
US11672858B2 (en) 2018-12-21 2023-06-13 Hoffmann-La Roche Inc. Bispecific antibody molecules binding to CD3 and TYRP-1
JP7530362B2 (ja) 2018-12-21 2024-08-07 カイマブ・リミテッド 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体
CN113412123A (zh) 2018-12-28 2021-09-17 豪夫迈·罗氏有限公司 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
SG11202105926QA (en) 2018-12-31 2021-07-29 Merus Nv Truncated multivalent multimers
PH12021551547A1 (en) 2018-12-31 2022-08-15 Merus Nv Mixed binding domains
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
WO2020159368A1 (en) 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
MX2021009769A (es) 2019-02-14 2021-09-08 Merus Nv Produccion de composiciones que comprenden dos o mas anticuerpos.
MA54944A (fr) 2019-02-14 2021-12-22 Merus Nv Combinaisons de fractions de liaison se liant à egfr, her2 et her3
CN114409798A (zh) * 2019-02-14 2022-04-29 美勒斯公司 制备包含两种或更多种抗体的组合物
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020224154B2 (en) 2019-02-21 2025-05-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
EP3927431A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
BR112021016955A2 (pt) 2019-03-01 2021-11-23 Xencor Inc Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
KR20210144837A (ko) * 2019-03-28 2021-11-30 에이비 스튜디오 인코포레이티드 이종다량체 단백질 및 이의 사용 방법
EP3947440A1 (en) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Method for generating avid-binding multispecific antibodies
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
EP3948281A1 (en) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Spr-based binding assay for the functional analysis of multivalent molecules
WO2020216879A1 (en) 2019-04-25 2020-10-29 F. Hoffmann-La Roche Ag Therapeutic multispecific polypeptides activated by polypeptide chain exchange
EP3959238A1 (en) 2019-04-25 2022-03-02 F. Hoffmann-La Roche AG Activatable therapeutic multispecific polypeptides with extended half-life
BR112021020843A2 (pt) * 2019-04-25 2022-02-01 Hoffmann La Roche Conjunto de polipeptídeos precursores heterodiméricos, polipeptídeos heterodiméricos, métodos para gerar um polipeptídeo heterodimérico e para identificar um polipeptídeo heterodimérico multiespecífico, polipeptídeo heterodimérico multiespecífico, primeiro e segundo polipeptídeo precursor heterodimérico
WO2020225456A1 (en) 2019-05-09 2020-11-12 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
NZ782091A (en) * 2019-05-09 2025-08-29 Merus Nv Variant domains for multimerizing proteins and separation thereof
EP3969907B1 (en) 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
JP7317353B2 (ja) * 2019-06-18 2023-07-31 株式会社プロテイン・エクスプレス ブレビバチルス菌によるヘテロ二量体タンパク質の生産
CN114080451B (zh) 2019-06-19 2024-03-22 豪夫迈·罗氏有限公司 通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
ES3027485T3 (en) 2019-06-26 2025-06-16 Hoffmann La Roche Mammalian cell lines with sirt-1 gene knockout
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
MX2022001049A (es) 2019-07-26 2022-05-03 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
KR20220039720A (ko) 2019-07-30 2022-03-29 오노 야꾸힝 고교 가부시키가이샤 이중 특이성 항체
CN114174338A (zh) 2019-07-31 2022-03-11 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
MX2022001156A (es) 2019-07-31 2022-02-22 Hoffmann La Roche Anticuerpos que se fijan a gprc5d.
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
US11787875B2 (en) 2019-08-15 2023-10-17 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
CN116333154A (zh) 2019-08-19 2023-06-27 美勒斯公司 用结合lgr5和egfr的抗体与拓扑异构酶i抑制剂的组合治疗癌症
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
EP4048702A1 (en) 2019-10-24 2022-08-31 Merus N.V. Means and methods for treating subjects with her2 and her3 positive cancer
US20220409730A1 (en) 2019-11-01 2022-12-29 InnoCore Technologies Holding B.V. Dosage form for extended release of an antibody or large protein
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
AU2020403913B2 (en) 2019-12-18 2024-10-10 F. Hoffmann-La Roche Ag Bispecific anti-CCL2 antibodies
CN114828965B (zh) 2019-12-18 2025-09-05 豪夫迈·罗氏有限公司 与hla-a2/mage-a4结合的抗体
CN114930170A (zh) 2020-01-02 2022-08-19 豪夫迈·罗氏有限公司 用于测定脑中的治疗性抗体量的方法
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
PE20230113A1 (es) 2020-01-16 2023-01-27 Genmab As Formulaciones de anticuerpos anti-cd38 y usos de las mismas
WO2021154073A1 (en) 2020-01-29 2021-08-05 Merus N.V. Means and method for modulating immune cell engaging effects.
IL295129A (en) 2020-01-30 2022-09-01 Umoja Biopharma Inc Bispecific transduction enhancer
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
UY40280A (es) 2020-03-13 2023-07-31 Janssen Biotech Inc Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides
CN115298221A (zh) 2020-03-18 2022-11-04 健玛保 结合b7h4的抗体
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021203103A2 (en) * 2020-04-03 2021-10-07 Somasekar Seshagiri Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
US20230192795A1 (en) 2020-04-15 2023-06-22 Hoffmann-La Roche Inc. Immunoconjugates
KR20230028242A (ko) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
EP4139357A1 (en) 2020-04-24 2023-03-01 Merus N.V. Treatment of cancers with an antibody that binds lgr5 and egfr
CA3180173A1 (en) 2020-04-30 2021-11-04 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN115916166A (zh) 2020-05-08 2023-04-04 健玛保 针对cd3和cd20的双特异性抗体
BR112022022614A2 (pt) 2020-05-11 2023-02-07 Hoffmann La Roche Métodos para estimular uma resposta imune, melhorar uma imunoterapia, tratar uma doença, reduzir crescimento tumoral, produzir um imunoconjugado e produzir uma composição, método de vacinação, imunoconjugados, composição, usos e kits
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4153315A1 (en) * 2020-05-21 2023-03-29 Merus N.V. Methods and means for the production of ig-like molecules
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
EP4168446A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Antibodies binding to cd3 and folr1
AR122658A1 (es) 2020-06-19 2022-09-28 Hoffmann La Roche Anticuerpos que se unen a cd3
IL296225A (en) 2020-06-19 2022-11-01 Hoffmann La Roche Immune activating fc domain binding molecules
MX2022016069A (es) 2020-06-19 2023-02-02 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19.
CN115867807B (zh) 2020-06-24 2025-10-31 旭化成生命科学股份有限公司 含蛋白质的溶液的评价方法
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CA3188601A1 (en) 2020-07-08 2022-01-13 LAVA Therapeutics N.V. Antibodies that bind psma and gamma-delta t cell receptors
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
JP2023536818A (ja) 2020-07-29 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
AU2021322046A1 (en) 2020-08-06 2023-02-02 BioNTech SE Binding agents for coronavirus S protein
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
CN116917316A (zh) 2020-08-26 2023-10-20 马伦戈治疗公司 与NKp30结合的抗体分子及其用途
WO2022047046A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
CA3192251A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CA3190349A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
IL301366A (en) 2020-09-24 2023-05-01 Hoffmann La Roche Mammalian cell lines with gene knockout
IL301513A (en) 2020-10-02 2023-05-01 Genmab As Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
US11926667B2 (en) 2020-10-13 2024-03-12 Janssen Biotech, Inc. Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
JP2023548034A (ja) 2020-10-22 2023-11-15 ヤンセン バイオテツク，インコーポレーテツド デルタ様リガンド３（ｄｌｌ３）抗原結合ドメインを含むタンパク質及びその使用
EP4240402A1 (en) 2020-11-04 2023-09-13 Merus N.V. Means and methods for treating subjects with erbb3 mutation positive cancer
US20240010748A1 (en) 2020-11-10 2024-01-11 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
IL303045A (en) 2020-12-10 2023-07-01 Lava Therapeutics N V Antibodies that bind gamma-delta t cell receptors
EP4263604A1 (en) 2020-12-15 2023-10-25 Merus N.V. Treatment of cancers with an antibody that binds lgr5 and egfr
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用
US20240058444A1 (en) 2020-12-18 2024-02-22 Merus N.V. Antibody composition
WO2022129313A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Precursor proteins and kit for targeted therapy
JP2024501662A (ja) 2020-12-22 2024-01-15 エフ． ホフマン－ラ ロシュ アーゲー Ｘｂｐ１を標的とするオリゴヌクレオチド
JP2024503826A (ja) 2021-01-06 2024-01-29 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１－ｌａｇ３二重特異性抗体及びｃｄ２０ ｔ細胞二重特異性抗体を用いる併用療法
CN117440969A (zh) * 2021-01-11 2024-01-23 阿迪马布有限责任公司 被工程化为优先进行ch3异源二聚化的变体ch3结构域、包括所述变体ch3结构域的多特异性抗体和其制备方法
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4295154A1 (en) 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions
WO2022180271A1 (en) 2021-02-26 2022-09-01 LAVA Therapeutics N.V. Antibodies that bind CD123 and gamma-delta T cell receptors
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
TW202304986A (zh) 2021-03-24 2023-02-01 美商健生生物科技公司 靶向cd22及cd79b的抗體
US12084501B2 (en) 2021-03-24 2024-09-10 Janssen Biotech, Inc. Proteins comprising CD3 antigen binding domains and uses thereof
EP4314061A1 (en) 2021-03-31 2024-02-07 Merus N.V. Novel multispecific antibodies
WO2022206872A1 (zh) 2021-03-31 2022-10-06 江苏恒瑞医药股份有限公司 截短的taci多肽及其融合蛋白和用途
EP4320147A4 (en) 2021-04-08 2025-06-18 Marengo Therapeutics, Inc. TCR-BINDING MULTIFUNCTIONAL MOLECULES AND USES THEREOF
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
MX2023012351A (es) 2021-05-07 2023-10-31 Genmab As Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3).
JP2024519324A (ja) * 2021-05-10 2024-05-10 メディミューン，エルエルシー 改善された半減期を有する改変ｆｃｒｎ結合フラグメント
KR20240006586A (ko) 2021-05-12 2024-01-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
US20240392020A1 (en) 2021-05-14 2024-11-28 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule
AU2022295067A1 (en) 2021-06-18 2023-12-21 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
IL309319A (en) 2021-06-21 2024-02-01 Genmab As Combined dosage regimen CD137 and PD-L1 binding agents
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
JP2024528573A (ja) 2021-07-14 2024-07-30 江蘇恒瑞医薬股▲ふん▼有限公司 Ｈｇｆｒとｅｇｆｒに特異的に結合する抗原結合分子及びその医薬使用
WO2023001884A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023006809A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
CN117715936A (zh) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 用于治疗癌症的方法和组合物
KR102351147B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
EP4399227A1 (en) 2021-09-06 2024-07-17 Genmab A/S Antibodies capable of binding to cd27, variants thereof and uses thereof
TW202328193A (zh) 2021-09-13 2023-07-16 美商健生生物科技公司 用於治療癌症的CD33 x Vδ2多特異性抗體
WO2023049732A1 (en) * 2021-09-21 2023-03-30 Qilu Puget Sound Biotherapeutics Corporation HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES
EP4406968A4 (en) 2021-09-23 2025-03-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-KLB ANTIBODIES AND USES
US20250019455A1 (en) 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
CA3233261A1 (en) 2021-09-30 2023-04-06 Langyong MAO Anti-il23 antibody fusion protein and uses thereof
JP2024537091A (ja) 2021-10-06 2024-10-10 メルス ナムローゼ フェンノートシャップ 少なくともｅｇｆｒに結合する抗体を使用した、免疫チェックポイント阻害剤で治療された高いｅｇｆｒ発現を有するがんの治療
IL311805A (en) 2021-10-08 2024-05-01 Genmab As Antibodies that bind to CD30 and CD3
PE20241627A1 (es) 2021-10-14 2024-08-07 Hoffmann La Roche Nuevos inmunoconjugados de interleucina-7
JP2024537096A (ja) 2021-10-14 2024-10-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための代替的なＰＤ１－ＩＬ７ｖイムノコンジュゲート
EP4419109A1 (en) 2021-10-21 2024-08-28 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
CN119613560A (zh) 2021-11-19 2025-03-14 美勒斯公司 包含PD-1和TGF-βRII结合域的多特异性结合部分
EP4436669A1 (en) 2021-11-22 2024-10-02 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
EP4437344A1 (en) 2021-11-25 2024-10-02 F. Hoffmann-La Roche AG Quantification of low amounts of antibody sideproducts
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
WO2023147784A1 (zh) 2022-02-07 2023-08-10 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
MX2024009715A (es) 2022-02-11 2024-08-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Inmunoconjugado y su uso del mismo.
KR20240151848A (ko) 2022-03-07 2024-10-18 메뤼스 엔.페. Egfr 및 cmet에 결합하는 항체를 사용한 치료
WO2023172133A1 (en) 2022-03-07 2023-09-14 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
US20250215083A1 (en) 2022-03-14 2025-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
KR20240164782A (ko) 2022-03-23 2024-11-20 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료
CA3255366A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
CA3253038A1 (en) 2022-05-12 2023-11-16 Genmab A/S LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
JP2025516633A (ja) 2022-05-12 2025-05-30 ジェンマブ エー／エス 併用療法においてｃｄ２７に結合する能力を有する結合剤
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4532526A1 (en) 2022-06-03 2025-04-09 F. Hoffmann-La Roche AG Improved production cells
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
WO2023246885A1 (zh) 2022-06-23 2023-12-28 江苏恒瑞医药股份有限公司 特异性结合dll3和cd3的抗原结合分子及其医药用途
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
WO2024030027A1 (en) 2022-08-05 2024-02-08 Merus N.V. Means and methods for treating castration-resistant prostate cancer
JP2025525885A (ja) 2022-08-05 2025-08-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｇｕｃｙ２ｃとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
CN120019277A (zh) 2022-10-12 2025-05-16 豪夫迈·罗氏有限公司 用于对细胞进行分类的方法
EP4612177A1 (en) 2022-10-31 2025-09-10 Genmab A/S Cd38 antibodies and uses thereof
TW202432596A (zh) 2022-11-01 2024-08-16 大陸商上海齊魯製藥研究中心有限公司 針對磷脂醯肌醇蛋白聚醣3的雙特異性抗體及其應用
KR20250097946A (ko) 2022-11-02 2025-06-30 얀센 바이오테크 인코포레이티드 암을 치료하는 방법
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024104933A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
JP2025537782A (ja) 2022-11-15 2025-11-20 エフ． ホフマン－ラ ロシュ アーゲー 活性化可能なエフェクタードメインを有する組換え結合タンパク質
CN120077072A (zh) 2022-11-29 2025-05-30 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途
AU2023410354A1 (en) 2022-12-20 2025-07-31 Incyte Corporation FAP BINDING DOMAINS AND BISPECIFIC BINDING MOIETIES THAT BIND FAP AND TGF-βRII
TW202432605A (zh) 2022-12-23 2024-08-16 荷蘭商美勒斯公司 使用至少結合ｅｇｆｒ的抗體和免疫檢查點抑制劑組合治療癌症
CN120344665A (zh) 2022-12-27 2025-07-18 中外制药株式会社 具有受控缔合的多肽
WO2024144401A1 (en) 2022-12-28 2024-07-04 Merus N.V. Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
EP4651885A1 (en) 2023-01-20 2025-11-26 F. Hoffmann-La Roche AG Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
TW202436339A (zh) 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
AU2024226611A1 (en) 2023-02-21 2025-08-28 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Il-36r binding protein and medicinal use thereof
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
CN120917044A (zh) 2023-04-03 2025-11-07 豪夫迈·罗氏有限公司 激动性拆分型抗体
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
WO2024213040A1 (zh) 2023-04-11 2024-10-17 浙江博锐生物制药有限公司 抗ror1抗体及其药物偶联物
AR132623A1 (es) 2023-05-08 2025-07-16 Hoffmann La Roche PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
AU2024271605A1 (en) 2023-05-12 2025-11-13 BioNTech SE Antibodies capable of binding to ox40, variants thereof and uses thereof
AU2024273454A1 (en) 2023-05-16 2025-11-27 F. Hoffmann-La Roche Ag Pd-1-regulated il-2 immunocytokine and uses thereof
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025007037A1 (en) 2023-06-28 2025-01-02 Dragonfly Therapeutics, Inc. Variant il-2 proteins
JP2025530208A (ja) 2023-06-30 2025-09-11 ジェンマブ エー／エス 線維芽細胞活性化タンパク質アルファおよびデスレセプター４に結合する抗体
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025024780A1 (en) 2023-07-27 2025-01-30 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025027511A1 (en) 2023-07-30 2025-02-06 Janssen Biotech, Inc. Molecules that bind to mutant calreticulin and uses thereof
US20250066510A1 (en) 2023-08-07 2025-02-27 Janssen Biotech, Inc. Gucy2c antibodies and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025137454A1 (en) * 2023-12-21 2025-06-26 Amgen Inc. Stabilizing homodimer mutations for two cell heterodimer production
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025188180A1 (en) 2024-03-04 2025-09-12 Merus N.V. Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression
WO2025202147A1 (en) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Interleukin-7 immunoconjugates
WO2025221138A1 (en) 2024-04-15 2025-10-23 Merus N.V. Cd3 binding domains
WO2025219504A1 (en) 2024-04-19 2025-10-23 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
WO2025230409A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2025230410A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies
WO2025231408A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025237931A1 (en) 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
CN121135878A (zh) 2024-06-14 2025-12-16 康诺亚生物医药科技（成都）有限公司 针对ox40l和il-13的双特异性抗体及其用途

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU600885B2 (en) 1984-05-25 1990-08-30 Zymogenetics Inc. Stable DNA constructs
EP0187045B1 (en) 1984-12-28 1991-07-31 Elf Atochem S.A. Radiation curable macromonomer printing inks
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
DE3889182T2 (de) 1987-08-24 1994-10-13 Wacom Co Ltd Koordinateneingabesystem mit einem Eingabeschreibstift.
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
FI884924L (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
DE3875456T3 (de) 1987-11-09 1998-06-10 Becton Dickinson Co Verfahren zur Analyse hämatopoietischer Zellen in einer Probe.
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
ATE99958T1 (de) 1989-06-08 1994-01-15 Wistar Inst Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
MC2211A1 (fr) 1989-12-01 1992-11-26 Genpharm Int Production de polypeptides recombinants par une espece bovine et procedes transgeniques
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH0568599A (ja) 1990-07-31 1993-03-23 Wistar Inst 遺伝子工学的に作られた抗体
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
JP3438889B2 (ja) 1991-03-29 2003-08-18 ジェネンテク，インコーポレイテッド 所望のタンパク質を高レベルに発現させる組換え宿主細胞の選別法
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE243747T1 (de) 1991-07-15 2003-07-15 Wellcome Found Herstellung von antikörpern
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP0669986B1 (en) 1992-11-13 2003-04-09 Idec Pharmaceuticals Corporation Fully impaired consensus kozac sequences for mammalian expression
WO1994023046A1 (en) 1993-04-07 1994-10-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP1149898A2 (en) 1993-12-23 2001-10-31 Infigen, Inc. Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
FR2717187B1 (fr) 1994-03-10 1996-05-31 Transgene Sa Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt.
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
JPH08116978A (ja) 1994-10-18 1996-05-14 Nisshinbo Ind Inc 抗体Ｆａｂライブラリーの作製法
DE69535557T2 (de) 1994-12-30 2008-04-30 Planet Biotechnology, Inc., San Diego Verfahren zur herstellung von schutzproteine enthaltende immunoglobuline und ihre verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
GB9621113D0 (en) 1996-10-10 1996-11-27 Univ Southampton Transgenic fish
WO1998024923A1 (en) 1996-12-02 1998-06-11 Wake Forest University Inactivation of hiv co-receptors as therapy for hiv infection
PT1712623E (pt) 1997-01-21 2011-12-21 Gen Hospital Corp Selecção de proteínas utilizando fusões de arn-proteína
JP2002512510A (ja) 1997-03-06 2002-04-23 インフィジェン・インコーポレーテッド 動物のクローニング方法
RO120148B1 (ro) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
SI1325932T1 (enExample) 1997-04-07 2005-08-31 Genentech Inc
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU747609B2 (en) 1997-09-23 2002-05-16 Oxford Biomedica (Uk) Limited Expression of genes in hematopoietic stem cells in hischaemic conditions
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
DE69823652D1 (de) 1997-11-26 2004-06-09 Mitsubishi Precision Co Ltd Informationsleitungssystem
US6147275A (en) 1998-03-30 2000-11-14 Research Development Foundation Corticotropin releasing factor receptor 1-deficient mice
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
WO2000044777A1 (en) 1999-01-29 2000-08-03 Imclone Systems Incorporated Antibodies specific to kdr and uses thereof
IL145849A0 (en) 1999-04-15 2002-07-25 Crucell Holland Bv Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
ATE421976T1 (de) 1999-05-18 2009-02-15 Dyax Corp Fab fragmentbibliotheken und verfahren für deren verwendung
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
BRPI0012198B8 (pt) 1999-06-25 2021-05-25 Genentech Inc anticorpos humanizados, composição e imunoconjugado
AU7491800A (en) 1999-09-15 2001-04-17 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
AU7676300A (en) 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
ATE353920T1 (de) 1999-12-27 2007-03-15 Crucell Holland Bv Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie
CA2401965A1 (en) 2000-02-29 2001-09-07 Auburn University Production of antibodies in transgenic plastids
AU2001257206B2 (en) 2000-04-26 2006-10-05 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
WO2001085796A2 (en) 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
DE60136174D1 (de) 2000-05-16 2008-11-27 Univ Jefferson Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren
NZ523080A (en) 2000-06-29 2004-11-26 Abbott Lab Antibodies specific for interleukin-1 alpha and interleukin-2 beta and methods of making and using
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
EP1188771A1 (en) 2000-09-15 2002-03-20 U-BISys B.V. Libraries of human heavy chain variable fragments in a functional format
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
FR2817875B1 (fr) 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
EP1356037B1 (en) 2001-01-25 2011-03-09 Evolva Ltd. A library of a collection of cells
ES2330201T3 (es) 2001-01-26 2009-12-07 Selexis S.A. Regiones de union a la matriz y metodos para el uso de las mismas.
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
CA2440676A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
DK1402025T3 (da) 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
WO2004003211A1 (en) 2002-06-26 2004-01-08 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
JP4500044B2 (ja) 2001-07-04 2010-07-14 クロマジェニックス ビー．ブイ． 遺伝子転写を調節する特性を含むｄｎａ配列及びそのようなｄｎａ配列を検出し且つ使用するための方法
AU2002332600B2 (en) 2001-08-21 2007-03-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
KR100968664B1 (ko) 2001-08-27 2010-07-06 제넨테크, 인크. 항체 발현 및 조립을 위한 시스템
HUP0402164A3 (en) 2001-11-16 2010-01-28 Biogen Idec Inc Polycistronic expression of antibodies
EP1451226A1 (en) 2001-11-30 2004-09-01 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
AU2002349228B2 (en) 2001-11-30 2007-06-14 National Research Council Of Canada Self-assembly molecules
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
GB2387030A (en) 2002-03-26 2003-10-01 Thales Plc Compensation of mutual coupling in array antenna systems
EP1510943A4 (en) 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc INTERACTION PREDICTION DEVICE
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
NZ537073A (en) 2002-06-14 2006-08-31 Chromagenics B A method for simultaneous production of multiple proteins; vectors and cells for use therein
EP1513936A2 (en) 2002-06-14 2005-03-16 Chromagenics B.V. Use of repression blocking sequences in methods for enhancing gene expression
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
CA2492067A1 (fr) 2002-07-10 2004-01-22 Agostino Di Trapani Element de construction
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
ATE536376T1 (de) 2003-12-23 2011-12-15 Crucell Holland Bv Humanes bindungsmolekül gegen cd1a
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
DK1749029T3 (da) 2004-05-27 2011-06-06 Crucell Holland Bv Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
BRPI0511782B8 (pt) 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
EP2279749B1 (en) 2004-10-12 2015-06-10 Crucell Holland B.V. Binding molecules for detection of aml
JP4487068B2 (ja) 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
EP1812067B1 (en) 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1893645A1 (en) 2005-06-23 2008-03-05 Crucell Holland B.V. Optimization of west nile virus antibodies
EP1928914A2 (en) 2005-09-15 2008-06-11 Crucell Holland B.V. Method for preparing immunoglobulin libraries
CN101370526B (zh) * 2005-11-28 2013-10-09 根马布股份公司 重组单价抗体及其制备方法
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
CA2654712C (en) 2006-06-06 2015-05-05 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
EP2024394B1 (en) 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
PT2235064E (pt) * 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
EP2245571B1 (en) 2008-02-05 2019-04-10 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
CN102123582B (zh) 2008-06-27 2015-09-30 莫鲁斯有限公司 产生抗体的非人哺乳动物
SG172977A1 (en) * 2009-01-26 2011-08-29 Genmab As Methods for producing mixtures of antibodies
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102448986B (zh) 2009-05-11 2015-11-25 克鲁塞尔荷兰公司 能中和流感病毒h3n2的人结合分子及其应用
KR20120027055A (ko) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US8765900B2 (en) 2009-08-27 2014-07-01 Bayer Materialscience Llc Aliphatic moisture-curable resins, coating compositions, and related processes
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
JP6022444B2 (ja) * 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
ES2946169T3 (es) 2011-02-25 2023-07-13 Regeneron Pharma Ratones ADAM6
AU2012235758B2 (en) 2011-03-25 2015-05-07 IGI Therapeutics SA Hetero-dimeric immunoglobulins
JP2013004215A (ja) 2011-06-14 2013-01-07 Hitachi Ltd リチウムイオン二次電池
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CA2865029A1 (en) 2012-03-06 2013-09-12 Regeneron Pharmaceuticals, Inc. Common light chain mouse
ES2740749T3 (es) * 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
AU2013271737A1 (en) 2012-06-05 2015-01-22 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
DK2900694T3 (en) * 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US10798961B2 (en) 2013-03-15 2020-10-13 Altria Client Services Llc Functional food and beverage compositions with improved taste through the use of sensates
JP7010811B2 (ja) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ ヒトｃｄ３結合抗体

Also Published As

Publication number Publication date
AU2013249986B2 (en) 2017-11-23
DK2838917T3 (da) 2019-08-26
SI2838918T1 (sl) 2019-11-29
JP6272299B2 (ja) 2018-01-31
JP7743173B2 (ja) 2025-09-24
SG11201406772YA (en) 2014-11-27
NZ728228A (en) 2021-02-26
MX2024012547A (es) 2024-12-06
NZ799532A (en) 2023-07-28
KR20230093359A (ko) 2023-06-27
CA2870821C (en) 2022-06-14
KR20200126007A (ko) 2020-11-05
CN108586610A (zh) 2018-09-28
US20240344102A1 (en) 2024-10-17
MX360110B (es) 2018-10-23
WO2013157954A1 (en) 2013-10-24
US9248182B2 (en) 2016-02-02
CN114163530A (zh) 2022-03-11
RS59263B1 (sr) 2019-10-31
SG11201406770WA (en) 2014-11-27
CN104520319A (zh) 2015-04-15
US11926859B2 (en) 2024-03-12
US20170327860A1 (en) 2017-11-16
KR20220046711A (ko) 2022-04-14
US12123043B2 (en) 2024-10-22
CY1122153T1 (el) 2020-11-25
JP2020202854A (ja) 2020-12-24
JP2023060019A (ja) 2023-04-27
US20140140999A1 (en) 2014-05-22
KR20150035534A (ko) 2015-04-06
CN104520320B (zh) 2018-05-01
SI2838917T1 (sl) 2019-11-29
CN104520320A (zh) 2015-04-15
JP2020089366A (ja) 2020-06-11
KR102382304B1 (ko) 2022-04-04
PT2838917T (pt) 2019-09-12
ES2743399T3 (es) 2020-02-19
NZ630568A (en) 2017-06-30
JP2015514417A (ja) 2015-05-21
US20130336981A1 (en) 2013-12-19
SG10201607371UA (en) 2016-10-28
JP2019022489A (ja) 2019-02-14
CA2871068C (en) 2022-06-14
EP2838918B1 (en) 2019-06-05
SMT201900493T1 (it) 2019-11-13
KR20200015756A (ko) 2020-02-12
JP6639464B2 (ja) 2020-02-05
US20170369923A1 (en) 2017-12-28
HUE045944T2 (hu) 2020-02-28
AU2018201326B2 (en) 2020-02-06
US10329596B2 (en) 2019-06-25
KR102171431B1 (ko) 2020-10-30
KR102104601B1 (ko) 2020-06-01
US20150139996A1 (en) 2015-05-21
SG10201913634VA (en) 2020-03-30
JP6393255B2 (ja) 2018-09-19
HRP20191409T1 (hr) 2019-11-15
SG10201913376XA (en) 2020-02-27
CA2870821A1 (en) 2013-10-24
EP2838918A1 (en) 2015-02-25
US20200017897A1 (en) 2020-01-16
AU2013249986A1 (en) 2014-11-06
PT2838918T (pt) 2019-08-23
KR20150035535A (ko) 2015-04-06
MX2014012701A (es) 2014-12-05
US9758805B2 (en) 2017-09-12
CY1122118T1 (el) 2020-11-25
JP2018099119A (ja) 2018-06-28
HK1206039A1 (en) 2015-12-31
EA035344B1 (ru) 2020-05-29
US20210071222A1 (en) 2021-03-11
AU2018201326A1 (en) 2018-03-15
CN114163530B (zh) 2025-04-29
JP2024180421A (ja) 2024-12-26
KR20230091201A (ko) 2023-06-22
KR102269650B1 (ko) 2021-06-28
SMT201900488T1 (it) 2019-11-13
EA202090591A2 (ru) 2020-08-31
US10337045B2 (en) 2019-07-02
AU2013249985A1 (en) 2014-11-06
EP2838917B1 (en) 2019-06-05
NZ802035A (en) 2025-02-28
CN120383672A (zh) 2025-07-29
AU2013249985B2 (en) 2017-11-23
EP3594232A1 (en) 2020-01-15
EP3594233A1 (en) 2020-01-15
JP6781740B2 (ja) 2020-11-04
CN107383197B (zh) 2021-12-10
CN107383197A (zh) 2017-11-24
SG10201607369QA (en) 2016-10-28
JP2025109759A (ja) 2025-07-25
LT2838917T (lt) 2019-09-25
US9358286B2 (en) 2016-06-07
US20160177364A1 (en) 2016-06-23
KR20200047724A (ko) 2020-05-07
AU2018201325A1 (en) 2018-03-15
US20230340556A1 (en) 2023-10-26
US9248181B2 (en) 2016-02-02
MX2025005214A (es) 2025-08-01
DK2838918T3 (da) 2019-08-12
MX2018012766A (es) 2021-11-16
CA2871068A1 (en) 2013-10-24
MX360109B (es) 2018-10-23
JP2015515275A (ja) 2015-05-28
HUE045945T2 (hu) 2020-02-28
AU2018201325B2 (en) 2020-02-06
ES2740749T3 (es) 2020-02-06
HK1206041A1 (en) 2015-12-31
KR20250025034A (ko) 2025-02-20
EA202090591A3 (ru) 2020-12-30
JP7723694B2 (ja) 2025-08-14
PL2838918T3 (pl) 2019-11-29
KR102545770B1 (ko) 2023-06-21
NZ630551A (en) 2017-11-24
HRP20191446T1 (hr) 2019-11-15
EA201491909A1 (ru) 2015-03-31
MX2024012548A (es) 2024-12-06
US10752929B2 (en) 2020-08-25
EP2838917A1 (en) 2015-02-25
RS59260B1 (sr) 2019-10-31
CN104520319B (zh) 2017-08-25
US20150196637A1 (en) 2015-07-16
MX2018012769A (es) 2021-11-16
EA201491908A1 (ru) 2015-03-31
ZA201407834B (en) 2015-12-23
WO2013157953A1 (en) 2013-10-24
MX2014012700A (es) 2014-12-05
LT2838918T (lt) 2019-09-10
NZ772318A (en) 2023-06-30
PL2838917T3 (pl) 2019-12-31
US20140072579A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
ZA201407835B (en) Methods an means for the production of ig-like molecules
EP3454346A3 (en) Apparatus for cylotron production of technetium-99m
PT2875062T (pt) Processo de síntese de poliarilétercetonas
IL234234B (en) 2ang binding molecules
ZA201502937B (en) Process for the preparation of hydrocarbons
SG10201703051WA (en) Compounds and methods for the production of suckerin and uses thereof
SG11201405572QA (en) Process for producing polydienes
HUE049113T2 (hu) Gyártási rendszer
IL236159A0 (en) Process for the production of methylbutanol
PL399419A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
IL236450A0 (en) Process for the preparation of 5-fluoro-h1-pyrazoles
PL2934172T3 (pl) Sposób oczyszczania lecytyny
HUP1200171A1 (hu) Módszerek polipeptidek elõállítására
ZA201405824B (en) Process for the preparation of substituted phenylpropanones
GB201215505D0 (en) Process for the production of ethanol
GB201202060D0 (en) Novel compounds and methods for their production
GB201216145D0 (en) Process for modifying membranes
HU229987B1 (en) Process for the preparation of pyrimidinyl-piperazines